My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about BSM

    SALT LAKE CITY, Aug. 10 /PRNewswire-FirstCall/ -- BSD Medical Corp.
 (Amex:   BSM) today announced that a newly published study conducted in
 Berlin, Germany involving 137 patients with advanced rectal cancer has
 shown that the addition of cancer treatments with the BSD-2000 to radiation
 and chemotherapy treatments did not result in any statistically significant
 adverse effect on patient quality of life compared to patients who received
 radiation and chemotherapy without the added treatment. The company was
 highly pleased with the results of these findings, especially in light of
 the substantial reduction of patient quality of life that can accompany
 other cancer therapies. BSD is a developer of new cancer treatment
 technology designed to make cancer treatment more effective without
 adversely impacting the quality of life for patients during treatments.
     The study was conducted using the Gastrointestinal Quality-of-Life
 Index (GIQLI), an instrument that has been validated and tested for its
 reproducibility and sensitivity in measuring quality of life for patients
 suffering from malignant and benign diseases of the gastrointestinal tract.
 The GIQLI contains nineteen questions pertaining to symptoms of disease,
 five questions relating to emotional well-being, seven questions regarding
 physical function, four questions that assess social function and six
 questions that measure the perception of the medical treatment. Of the 137
 patients, 68 (49.6%) received treatments with radiation, chemotherapy and
 the BSD-2000 and 69 (50.4%) were treated with radiation and chemotherapy
 alone. The global GIQLI scores showed no significant differences at any
 time point pertaining to quality of life for the two groups. Quality of
 patient life during cancer treatment has become an increasing priority for
 both patients and providers, and the company considers these finding very
 significant.
     BSD Medical Corp. is a leading developer of systems that deliver
 precision-focused microwave/RF energy to heat diseased sites in the body,
 raising them to therapeutic temperatures as required for a variety of
 medical treatments, including cancer. BSD's cancer treatment systems were
 developed and have been tested in many clinical trials as an additive
 therapy to radiation and/or chemotherapy, used to kill cancer with mild
 heat and create conditions in tumors that allow these companion therapies
 to more effectively destroy cancer. Heat forces increased blood flow into
 tumors, oxygenating the tumor so that the oxygen radicals required to
 attack cancer cell DNA can be adequately formed during radiation
 treatments. Increased tumor blood flow also allows blood-borne chemotherapy
 drugs to enter and better permeate the tumor. Many studies have shown
 significantly improved tumor response and control and/or patient survival
 with the addition of heat therapy in treating certain cancers. Further
 details can be obtained on BSD Medical's website www.BSDMedical.com or the
 company's patient website www.treatwithheat.com.
     BSD Medical Corp. acknowledges Drs. Schultze, Wust, Gellermann,
 Hilderbrandt, Riess, Felix and Rau, all affiliated with Charite University
 Medical School in Berlin, Germany, as authors of this study entitled,
 "Influence of neoadjuvant radiochemotherapy combed with hyperthermia on the
 quality of life in rectum cancer patients." The study was published in the
 International Journal of Hyperthermia, vol. 22(4), pp. 301-318. The
 International Journal of Hyperthermia is the official journal of the
 Society of Thermal Medicine, the European Society for Hyperthermic Oncology
 and the Asian Society of Hyperthermic Oncology.
     Statements contained in this press release that are not historical
 facts are forward-looking statements, as that item is defined in the
 Private Securities Litigation Reform Act of 1995. All forward-looking
 statements and projections or expectations of future events, including the
 prospects for future sales of the Company's cancer therapy systems based on
 studies involving the Company's treatment systems are subject to risks and
 uncertainties detailed in the Company's filings with the Securities and
 Exchange Commission.
 
 

SOURCE BSD Medical Corp.